# Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant

> **NCT03961919** · PHASE2 · COMPLETED · sponsor: **Ciceri Fabio** · enrollment: 15 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Transplant-Related Hematologic Malignancy

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** ARA-C
- **DRUG:** Treosulfan
- **PROCEDURE:** Peripheral Blood Stem Cell Transplant

## Key facts

- **NCT ID:** NCT03961919
- **Lead sponsor:** Ciceri Fabio
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02-10
- **Primary completion:** 2019-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03961919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03961919, "Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03961919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*